When an Increase in Central Systolic Pressure Overrides the Benefits of Heart Rate Lowering.

Messerli, Franz H; Rimoldi, Stefano; Bangalore, Sripal; Bavishi, Chirag; Laurent, Stephane (2016). When an Increase in Central Systolic Pressure Overrides the Benefits of Heart Rate Lowering. Journal of the American College of Cardiology, 68(7), pp. 754-762. Elsevier 10.1016/j.jacc.2016.03.610

Text 1-s2.0-S073510971633488X-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (928kB) | Request a copy

An elevated resting heart rate has been unequivocally linked to adverse cardiovascular events. Conversely, a physiologically low heart rate may confer longevity benefits. Moreover, pharmacological heart rate lowering reduces cardiovascular outcomes in patients with heart failure, with the magnitude of the reduction associated with survival benefit. In contrast, pharmacological heart rate lowering paradoxically increases cardiovascular events in hypertension, possibly because it elicits a ventricular-vascular mismatch, leading to increased central systolic blood pressure (BP). By the same hemodynamic mechanism, pharmacological heart rate lowering also engenders an increase in central (aortic) BP in coronary heart disease and, as a consequence, fails to decrease myocardial oxygen consumption. Whether in heart failure, hypertension, or coronary heart disease, or even athletes, heart rate lowering consistently increases central systolic pressure. The increase in central systolic BP is prone to abolish the potential benefits of heart rate lowering interventions, possibly accounting for failure to reduce outcomes in patients with hypertension and coronary artery disease.

Interest & Impact

Downloads

1 since deposited on 16 May 2017
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item